General Information of Drug Combination (ID: DCVRVAO)

Drug Combination Name
SCH 727965 RTB101
Indication
Disease Entry Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour Investigative [1]
Component Drugs SCH 727965   DMCJLD1 RTB101   DM62QTW
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: ES2
Zero Interaction Potency (ZIP) Score: 6.87
Bliss Independence Score: 4.9
Loewe Additivity Score: 2.41
LHighest Single Agent (HSA) Score: 9.71

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SCH 727965
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Discontinued in Phase 3 [2]
SCH 727965 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [5]
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [5]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
SCH 727965 Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Phosphorylation [6]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [6]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [7]
Breast cancer type 2 susceptibility protein (BRCA2) OTF1XSV1 BRCA2_HUMAN Decreases Expression [7]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Decreases Expression [7]
Fanconi anemia group D2 protein (FANCD2) OTVEB5LF FACD2_HUMAN Decreases Expression [7]
Cyclin-dependent kinase 12 (CDK12) OTZUDGNU CDK12_HUMAN Decreases Activity [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast and ovarian cancer syndrome DC6OAUB UWB1289 Investigative [9]
Breast and ovarian cancer syndrome DC9YP2G UWB1289+BRCA1 Investigative [9]
Breast carcinoma DC932MB KPL1 Investigative [9]
Breast carcinoma DCE2309 OCUBM Investigative [9]
Carcinoma DCZPD8J EFM192B Investigative [9]
Carcinoma DCUI5MH MDAMB436 Investigative [9]
Colon adenocarcinoma DC1G1GT LOVO Investigative [9]
Colon carcinoma DCFWUUJ RKO Investigative [9]
Rectal adenocarcinoma DCIYXJ2 SW837 Investigative [9]
Adenocarcinoma DCZPUJP CAOV3 Investigative [10]
Adenocarcinoma DCG8JG3 A427 Investigative [10]
Adenocarcinoma DCQGR5Z NCIH1650 Investigative [10]
Adenocarcinoma DCKTMAI NCIH23 Investigative [10]
Adenocarcinoma DCKTV40 NCIH520 Investigative [10]
Adenocarcinoma DCO4K1X COLO320DM Investigative [10]
Adenocarcinoma DCN0FCN DLD1 Investigative [10]
Adenocarcinoma DCTTJO9 HCT116 Investigative [10]
Adenocarcinoma DCFPIIA HT29 Investigative [10]
Adenocarcinoma DCEGMN5 SW-620 Investigative [10]
Amelanotic melanoma DCWCVOI A2058 Investigative [10]
Germ cell tumour DCHBUCT PA1 Investigative [10]
Large cell lung carcinoma DCI057A NCI-H460 Investigative [10]
Malignant melanoma DC38Q9O A375 Investigative [10]
Malignant melanoma DCZ590L HT144 Investigative [10]
Malignant melanoma DCLY1M6 RPMI7951 Investigative [10]
Malignant melanoma DCBBX9G SKMEL30 Investigative [10]
Malignant melanoma DCHBIG2 UACC62 Investigative [10]
Mesothelioma DCDAWN4 MSTO Investigative [10]
Non small cell carcinoma DCB2QR9 SKMES1 Investigative [10]
Ovarian endometrioid adenocarcinoma DCYZG6H A2780 Investigative [10]
Ovarian serous cystadenocarcinoma DCNHMMU SK-OV-3 Investigative [10]
Prostate carcinoma DCH3S9D LNCAP Investigative [10]
Prostate carcinoma DCRSEZH VCAP Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7379).
3 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
5 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
6 Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010 Aug;9(8):2344-53. doi: 10.1158/1535-7163.MCT-10-0324. Epub 2010 Jul 27.
7 CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
8 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
10 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.